RxDoctor Payments Data

Cynthia Lewin

Family · Sergeant Bluff, IANPI 1962467456

Payments from drug & device makers

$2,371in general payments, 2019–2025

Across 76 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$309
  • AstraZeneca$248
  • GSK$214
  • AbbVie$205
  • Amgen$163
  • Biohaven Pharmaceuticals, Inc.$139
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,34499%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,371 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$83,480
Medicare patients
163
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$57,609
OzempicSemaglutide29$32,616
JardianceEmpagliflozin21$28,429
MounjaroTirzepatide14$22,004
JanuviaSitagliptin Phosphate11$18,306
TrulicityDulaglutide12$13,740
XareltoRivaroxaban11$11,881
Breo ElliptaFluticasone/Vilanterol12$9,176
MyrbetriqMirabegron12$8,894
OxycontinOxycodone Hcl11$6,456
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$4,970
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,714
CreonLipase/Protease/Amylase12$3,914
Dexlansoprazole DrDexlansoprazole19$3,855
Tegretol XrCarbamazepine26$3,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$57,609133 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$25$36,98840 claims
Novo NordiskOzempic$117$32,61629 claims
Boehringer IngelheimJardiance$309$28,42921 claims
MerckJanuvia$122$18,30611 claims
Johnson & JohnsonXarelto$93$11,88111 claims
GSKBreo Ellipta$214$9,17612 claims
Astellas Pharma US IncMyrbetriq$118$8,89412 claims
AstraZenecaBevespi Aerosphere$248$4,97012 claims
AbbVieCreon$205$3,91412 claims
Sanofi-aventis U.S. LLCLantus$12$1,56723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.

Other family in Sergeant Bluff

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →